Patents Examined by Brad Duffy
  • Anti-TEM1 antibodies and uses thereof
    Patent number: 11078285
    Abstract: The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: December 24, 2018
    Date of Patent: August 3, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nathalie Scholler, Aizhi Zhao, Donald Siegel, George Coukos
  • Combination therapy for the treatment of cancer
    Patent number: 11078279
    Abstract: This invention relates to a pharmaceutical composition that comprises a first molecule that specifically binds HER2/neu and a second molecule that specifically binds a cell-surface receptor (or its ligand) that is involved in regulating an immune checkpoint (or the ligand thereof). The invention particularly relates to the embodiment wherein the second molecule binds to PD-1. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 3, 2021
    Assignee: MacroGenics, Inc.
    Inventors: Jon Marc Wigginton, Naimish Bharat Pandya, Robert Joseph Lechleider, Scott Koenig, Ezio Bonvini
  • CD70 binding molecules and methods of use thereof
    Patent number: 11046775
    Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 29, 2021
    Assignee: Kite Pharma, Inc.
    Inventors: Ruben Alvarez Rodriguez, Armen Mardiros
  • EGFR-directed car therapy for glioblastoma
    Patent number: 11045543
    Abstract: Glioblastoma (GB) remains the most aggressive primary brain malignancy; brain metastasis, such as breast cancer brain metastases (BCBMs), are also aggressive and are associated with poor prognosis. Adoptive transfer of chimeric antigen receptor (CAR)-modified immune cells has emerged as a promising anti-cancer approach, yet the potential utility of CAR-engineered cells to treat brain cancers has not been explored. The present disclosure presents compostions and methods for using CAR expressing cells in the treatment of various cancers, including brain cancers such as GB and BCBMs.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: June 29, 2021
    Assignee: CYTOIMMUNE THERAPEUTICS, INC.
    Inventors: Jianhua Yu, Michael Caligiuri
  • Antibody specifically binding to PAUF protein and use thereof
    Patent number: 11046779
    Abstract: The present invention provides antibodies which specifically bind to pancreatic adenocarcinoma upregulated factor (PAUF) protein and uses thereof.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 29, 2021
    Assignees: DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION, PRESTIGE BIOPHARMA PTE. LTD.
    Inventors: Sang Seok Koh, Yeon Jeong Kim, So Eun Youn, Song Cheol Kim, Seung-Mo Hong, Seong Yun Jeong
  • Cell surface coupling of nanoparticles
    Patent number: 11034752
    Abstract: The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 15, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Darrell J. Irvine, Yiran Zheng, Li Tang
  • Cancer vaccines and methods of treatment using the same
    Patent number: 11007255
    Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 18, 2021
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventor: Jian Yan
  • Chimeric antigen receptor for efficient selective proliferation in vitro and uses thereof
    Patent number: 11001639
    Abstract: Chimeric antigen receptors for efficient and selective in vitro proliferation and uses thereof. Specifically, the present invention provides a CAR-encoding molecule with specific selectivity in vitro. By introducing a humanized selective domain into the molecule, the CAR-positive cells after being infected can be efficiently sorted via a secondary sorting step. Upon exposure to the selective domain-specific antibody, the CAR-transduced immune cells can be selectively expanded; therefore, the ratio of the CAR-positive target cells in the final product is significantly increased, improving the efficiency of preparing CAR gene-modified immune cell products. The present invention provides a more reliable technical support for further promotion and application of such products in clinical practice.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 11, 2021
    Assignee: Xuanwu Hospital Capital Medical University
    Inventors: Zhiguo Chen, Yu Zhao
  • Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
    Patent number: 11001642
    Abstract: Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 11, 2021
    Inventors: Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 11000550
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: May 11, 2021
    Assignee: NANTKWEST, INC.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Tetravalent antibody-drug conjugates and use thereof
    Patent number: 10994021
    Abstract: An antibody-drug conjugate (ADC) or a pharmaceutically acceptable salt thereof, is provided. The ADC includes a tetravalent monoclonal antibody conjugated to a cytotoxic drug by a chemical linker. The monoclonal antibody includes two long chains and four short chains. Each of the long chains includes a first segment and a second segment, the first segment located proximal to the N-terminus of the long chain, and the second segment located proximal to the C-terminus of the long chain. Each of the first segment and second segment pairs with one of the short chains to form an antigen-binding fragment domain, therefore forming four antigen-binding fragment domains having specificity toward the same antigen. Pharmaceutical composition including the ADC and methods of treating diseases using the compositions are also provided.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: May 4, 2021
    Assignee: Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
    Inventors: Yuhong Zhou, Ziping Wei
  • Anti P2Xreceptor antibodies and fragments thereof
    Patent number: 10988532
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 27, 2021
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • PD-1 antibodies and uses thereof
    Patent number: 10981991
    Abstract: The present invention provides monoclonal antibodies that specifically bind to human PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. The PD-1 antibodies of the present invention inhibit the binding of PD-L1 to PD-1, thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The invention also provides methods for treating various diseases, including infectious diseases and cancer using the PD-1 antibodies of the present invention.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: April 20, 2021
    Assignee: SHANGHAI ZHANGJIANG BIOTECHNOLOGY CO., LTD.
    Inventors: Nana Gu, Ke Shao
  • Bispecific antibody targeting human p185 and vascular endothelial growth factor and application thereof
    Patent number: 10973916
    Abstract: A bispecific antibody that simultaneously targets humanized p185 and VEGF, consisting of the four peptide chains: two identical antibody light chains that are the light chains of the antibody that identify the epitope or antigen of p185, and two identical antibody heavy chains that have the amino acid sequence of a recombinant antibody from N- to C-terminus, a light chain sequence of the antibody that recognizes the p185 epitope or the antigen; a constant heavy chain region; a flexible short peptide sequence; and either a single-stranded variable region sequence (ScFv) of anti-VEGF antibody which recognizes the VEGF epitope or antigen, or a receptor domain sequence that binds to VEGF. The bispecific antibody has the ability to bind p185 and VEGF at the same time, inhibits the proliferation of tumor cells, and promotes the expression of IFN-? by T lymphocytes; it may be applied as anti-tumor antibody drug.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: April 13, 2021
    Assignee: Sun-Bio Medical Device Co., Ltd.
    Inventors: Yang Yang, Wei Yin
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 10968280
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 6, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz
  • Anti-GCC antibody molecules and related compositions and methods
    Patent number: 10941211
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 9, 2021
    Assignees: MILLENNIUM PHARMACEUTICALS, INC., AMGEN BRITISH COLUMBIA INC.
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
    Patent number: 10942185
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 9, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark P. Chao, Rachel Weissman-Tsukamoto, Siddhartha Jaiswal, Ravindra Majeti, Irving L. Weissman
  • Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
    Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Chimeric antigen receptors based on single domain antibodies and methods of use thereof
    Patent number: 10934363
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 2, 2021
    Assignee: Legend Biotech USA Inc.
    Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
  • B cell maturation antigen binding proteins
    Patent number: 10927180
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: February 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin